sargramostim Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
granulocyte macrophage colony stimulating factor (GM-CSF) types substances 5025 123774-72-1

Description:

MoleculeDescription

Synonyms:

  • sargramostim
  • sargramostim (genetical recombination)
  • leukine
  • BI 61.012
a glycosylated form of recombinant GM-CSF; used to treat drug-induced agranulocytosis; amino acid sequence known
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.45 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 5, 1991 FDA BERLEX LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperhidrosis 29.79 29.03 20 939 89288 46595815

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bone pain 33.98 26.54 17 1397 19009 29932055
Chills 28.35 26.54 25 1389 72313 29878751

Pharmacologic Action:

SourceCodeDescription
ATC L03AA09 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Colony stimulating factors
FDA CS M0024695 Granulocyte-Macrophage Colony-Stimulating Factor
FDA CS M0024696 Granulocyte Colony-Stimulating Factor
FDA PE N0000009451 Increased Myeloid Cell Production
FDA EPC N0000175666 Leukocyte Growth Factor
MeSH PA D007155 Immunologic Factors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced neutropenia indication 425229001

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Granulocyte macrophage colony-stimulating factor receptor Membrane receptor AGONIST Kd 8.30 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D05803 KEGG_DRUG
4019558 VUID
N0000147658 NUI
4019558 VANDF
C0701500 UMLSCUI
CHEMBL1201670 ChEMBL_ID
C081222 MESH_SUPPLEMENTAL_RECORD_UI
7905 IUPHAR_LIGAND_ID
6842 INN_ID
DB00020 DRUGBANK_ID
5TAA004E22 UNII
203878 RXNORM
1744 MMSL
5443 MMSL
d00513 MMSL
003580 NDDF
108967001 SNOMEDCT_US
388375003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Leukine HUMAN PRESCRIPTION DRUG LABEL 1 0024-5843 INJECTION, POWDER, FOR SOLUTION 250 ug SUBCUTANEOUS BLA 29 sections
Leukine HUMAN PRESCRIPTION DRUG LABEL 1 0024-5844 LIQUID 500 ug SUBCUTANEOUS BLA 29 sections
Leukine HUMAN PRESCRIPTION DRUG LABEL 1 71837-5843 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 ug SUBCUTANEOUS BLA 29 sections
Leukine HUMAN PRESCRIPTION DRUG LABEL 1 71837-5844 INJECTION, SOLUTION 500 ug SUBCUTANEOUS BLA 29 sections